BJ: has received speaker and consulting fees from Merck-Serono, Biogen, Teva, Genzyme and Novartis ... MV: received grants from ZonMw, Alzheimer Nederland, Weston Brain Institute, NIH. AP: member of ...

The diagnostic groups comprised: ALS (n=75), frontotemporal lobar degeneration (FTLD) (n=33), Alzheimer’s disease ... and has received funding for travel and speaker honoraria from Lilly GmbH, Daiichi ...

In the first major deal at MIT’s ambitious overhaul of the old Volpe Center in Kendall Square, Cambridge drugmaker Biogen ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.

SEVEN NEWS. MORE THAN 53,000 NEW MEXICANS ARE EXPECTED TO HAVE ALZHEIMER’S DISEASE BY 2025. THE ALZHEIMER’S ASSOCIATION SAYS THAT’S AN INCREASE OF 2000 PEOPLE PER YEAR. WE ASKED KOAT ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

A puzzling discovery has left doctors scratching their heads: The brain of an American woman with Down syndrome showed all the classic signs of Alzheimer’s disease, yet she remained symptom-free ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...